UNI-PHARMA has been granted a European Patent (EP4181693B1) for Hepatrat®, an innovative dietary supplement in a bilayer tablet formulation.

Hepatrat® contains vitamin C, vitamin E, choline, and a natural extract of Ampelopsis grossedentata, standardized to a stable content of dihydromyricetin (DHM).

This formulation has been specifically designed to support normal liver function, contribute to the physiological function of hepatocytes, and promote normal lipid metabolism, through a combination of ingredients with well-documented antioxidant and anti-inflammatory properties.

The efficacy and safety of Hepatrat® were evaluated in a 12-month randomized, double-blind, placebo-controlled clinical trial, conducted in Greece in outpatient hepatology clinics of three major hospitals in Athens (Laiko General Hospital, Attikon University Hospital, and Evangelismos Hospital).

The study included adult patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), also known as fatty liver disease, a condition affecting approximately 25–30% of the global population.

The results of the study, conducted by Professor of Internal Medicine–Gastroenterology at the National and Kapodistrian University of Athens Medical School, Georgios Papatheodoridis, and his colleagues, were published in Annals of Gastroenterology, the official journal of the Hellenic Society of Gastroenterology.

Patients receiving Hepatrat® demonstrated a statistically significant improvement in liver enzymes ALT and GGT, with markedly higher rates of simultaneous normalization compared with the placebo group.

In parallel, a significant reduction in liver stiffness was observed, as assessed by elastography techniques (transient elastography and 2D shear-wave elastography), along with favorable effects on metabolic parameters, including improvements in glucose levels and total and LDL cholesterol.

Long-term administration of the supplement was safe and well tolerated, with no adverse events reported.